Source: Patient Worthy Challenges Unique to Cell and Gene Therapies (CGTx) Clinical Trials Cell and gene therapies (CGTx) have emerged as a novel and advanced
Source: Healthcare Business Today Cell and gene therapies (CGTx) hold immense promise as transformative treatments for a wide range of diseases. However, the successful translation
Delays in clinical trials, worsened by the Inflation Reduction Act (IRA), are now a challenge to patient access to new therapies. Evolving complex regulatory requirements,
Source: PR Web President Biden’s loss of his beloved son to brain cancer in 2015 inspired the Cancer Moonshot initiative. Dr. Harsha Rajasimha’s inspiration for
Innovative technologies have revolutionized how clinical trials are conducted, catering to a diverse range of participants while ensuring patient-centricity remains a top priority. Embracing decentralized
Clinical trial sponsors need reliable patient data to ensure compliance and adhere to the regional and national guidelines. While the complexities persist in clinical trials,
In the bustling world of clinical research, where every discovery holds the promise of a brighter future, patient engagement and compliance stand as the guiding
Source: American Pharmaceutical Review In recent years, transformative strides in the treatment of sickle cell disease (SCD) have materialized with the FDA’s approval of groundbreaking
Source: Western Pennsylvania Healthcare News The recent Food and Drug Administration (FDA) approval of cell-based gene therapies for Sickle Cell Disease (SCD) marks a groundbreaking
Source: Rare Disease and Orphan Drug Journal Abstract One of the main challenges in rare diseases is the unavailability of reliable estimates of prevalence and
Jeeva Clinical Trials Inc.
